The fight against gonorrhea, a common sexually transmitted infection, received a significant boost in late 2025 with the U.S. Food and Drug Administration (FDA) approving two new oral treatments: gepotidacin (Blujepa) and zoliflodacin (Nuzolvence). These approvals mark the first time in over three decades that completely new antibiotics have been introduced to combat this increasingly drug-resistant infection. The emergence of these new therapies comes at a critical time, following warnings from the World Health Organization (WHO) about the growing global threat of antibiotic resistance.
Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, is a widespread public health concern. An estimated 82 million people are infected globally each year, and the Centers for Disease Control and Prevention (CDC) estimates 1.6 million cases occur annually in the United States. Many individuals with gonorrhea experience no symptoms, contributing to its silent spread. Untreated infections can lead to serious health complications, including infertility in both men and women, highlighting the importance of effective treatment options.
The Rising Challenge of Antibiotic Resistance
For years, gonorrhea has demonstrated a remarkable ability to evolve and overcome antibiotic treatments. The bacterium has developed resistance to a range of drugs, including sulfanilamides, penicillins, tetracyclines, and fluoroquinolones. Currently, the standard treatment relies on an injection of ceftriaxone, a cephalosporin antibiotic, sometimes combined with a dose of azithromycin, though current guidelines often recommend ceftriaxone alone. The increasing resistance to existing antibiotics has fueled the urgent require for new therapeutic approaches.
Both gepotidacin and zoliflodacin represent a new class of antibiotics, offering a different mechanism of action than those previously used to treat gonorrhea. Importantly, both drugs are administered orally, which simplifies treatment and improves accessibility compared to injectable medications.
Blujepa (Gepotidacin): A Dual-Purpose Antibiotic
Gepotidacin, marketed as Blujepa, was initially approved by the FDA in March 2025 for the treatment of uncomplicated urinary tract infections. Its subsequent approval for gonorrhea expands its clinical utility. The treatment regimen involves eight pills taken in two doses.
In a clinical trial involving 628 patients with gonorrhea, Blujepa demonstrated comparable efficacy to the current standard treatment. Specifically, 93% of patients treated with Blujepa achieved a cure, compared to 91% of those receiving ceftriaxone and azithromycin. Whereas patients taking Blujepa reported a higher incidence of side effects, such as diarrhea and nausea, these were generally mild in nature.
Nuzolvence (Zoliflodacin): A Single-Dose Solution
Zoliflodacin, sold under the name Nuzolvence, offers a convenient single-dose treatment option. The medication is administered as a powder dissolved in water. Research indicates that Nuzolvence also achieves similar cure rates to the standard treatment. A study of 930 patients showed that 91% were cured one week after receiving Nuzolvence, compared to 96% of patients treated with ceftriaxone and azithromycin.
The development of Nuzolvence is particularly noteworthy. It was a collaborative effort between the Global Antibiotic Research and Development Partnership (GARDP), a nonprofit established by the WHO, and Innoviva Specialty Therapeutics, a U.S.-based company. GARDP’s mission is to foster the development of new antibiotics, recognizing the limited financial incentives often associated with these drugs. Nuzolvence was specifically designed to combat antibiotic resistance in gonorrhea and will be used exclusively for this purpose, a deliberate strategy to minimize overuse and further resistance development.
Public health experts have welcomed these new treatments. Edward Hook, MD, an emeritus professor of medicine at the University of Alabama and former board member of the American Sexual Health Association (ASHA), emphasized the significance of these approvals, stating, “It’s been more than 30 years since the FDA approved a new antibiotic for gonorrhea treatment. At a time when antibiotic resistance is increasing worldwide, having new oral antibiotics effective against antibiotic resistant gonorrhea is a great addition to care for persons with an at risk for STIs.”
As gepotidacin is an acetylcholinesterase inhibitor, the FDA notes there is potential for an exaggerated effect when used with succinylcholine-type neuromuscular blocking agents, potentially delaying recovery of neuromuscular function. It may also augment the effects of other acetylcholinesterase inhibitors, such as donepezil.
The availability of Blujepa and Nuzolvence represents a crucial step forward in addressing the growing challenge of gonorrhea and protecting public health. The FDA will continue to monitor the effectiveness of these treatments and assess the ongoing threat of antibiotic resistance. Further research and surveillance will be essential to ensure these new therapies remain effective for years to come.
The FDA is scheduled to host a public workshop on antimicrobial resistance in early March 2026, where experts will discuss strategies for combating drug-resistant infections, including gonorrhea. Readers are encouraged to share their thoughts and experiences with STIs in the comments below.
